Advertisement


Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).



Related Videos

Breast Cancer

Stephen R.D. Johnston, MBBS, PhD, and Ann H. Partridge, MD, on Breast Cancer: Managing Metastatic ER+ Disease

Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).

Breast Cancer

Eric P. Winer, MD: The McGuire Lecture

Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.

Breast Cancer
Symptom Management

Patricia A. Ganz, MD: Aromatase Inhibitors Data Review

Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).

Symptom Management
Breast Cancer

Jame Abraham, MD, on Hair Loss: SCALP Trial Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).

Breast Cancer
Symptom Management

Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease

Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).

Advertisement

Advertisement



Advertisement